691857-51-9

Basic information

• Product Name: ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate
• Synonyms: ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate
• CAS NO: 691857-51-9
• Molecular Weight: 477.347
• Mol File: 691857-51-9.mol

Chemical Properties

• CAS DataBase Reference: ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate(691857-51-9)
• EPA Substance Registry System: ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate(691857-51-9)

Safety Data

• Hazardous Substances Data: 691857-51-9(Hazardous Substances Data)

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 691857-46-2 ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 691857-07-5 ethyl 2-(4-fluorophenyl)-5-isopropoxy-6-nitrobenzofuran-3-carboxylate 
• 691856-87-8 ethyl 2-(4-fluorophenyl)-5-isopropoxybenzofuran-3-carboxylate 
• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 691856-86-7 ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate 

Downstream Products

• 691857-52-0 ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate 
• 1217339-14-4 ethyl 5-(3-(tert-butoxycarbonyl)phenyl)-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate 
• 1383854-31-6 4-(N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(1H-imidazol-2-yl)benzofuran-6-yl)methylsulfonamido)butanoyl chloride 
• 1383853-95-9 5-cyclopropyl-2-(4-fluorophenyl)-6-(N-isopentylmethylsulfonamido)benzofuran-3-carboximidamide 
• 1383854-22-5 N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(5-methyl-1H-imidazol-2-yl)-1-benzofuran-6-yl]-N-(3-methylbutyl)methanesulfonamide 
• 1383854-21-4 N-{5-cyclopropyl-2-(4-fluorophenyl)-3-[4-(trifluoromethyl)-1H-imidazol-2-yl]-1-benzofuran-6-yl}-N-(3-methylbutyl)methane sulfonamide 
• 1383851-49-7 N-[5-cyclopropyl-3-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)-2-(4-fluorophenyl)-1-benzofuran-6-yl]-N-(4-hydroxybutyl)methanesulfonamide 
• 1383851-57-7 N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-N-[5-cyclopropyl-3-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)-2-(4-fluorophenyl)-1-benzofuran-6-yl]methanesulfonamide 
• 1383851-55-5 N-[5-cyclopropyl-3-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)-2-(4-fluorophenyl)-1-benzofuran-6-yl]-N-(4-methoxybenzyl)methanesulfonamide 
• 1383851-54-4 N-{3-[4-(2-chloroethyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-6-yl}-N-(4-methoxybenzyl)methanesulfonamide 
• 1383851-53-3 N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1-benzofuran-6-yl]-N-(4-methoxybenzyl)methanesulfonamide 
• 1383851-52-2 5-cyclopropyl-2-(4-fluorophenyl)-N'-hydroxy-6-[(4-methoxybenzyl)(methylsulfonyl)amino]-1-benzofuran-3-carboximidamide 
• 1383851-51-1 N-[3-cyano-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-6-yl]-N-(4-methoxybenzyl)methanesulfonamide 
• 1383851-50-0 N-{5-cyclopropyl-2-(4-fluorophenyl)-3-[(hydroxyimino)methyl]-1-benzofuran-6-yl}-N-(4-methoxybenzyl)methanesulfonamide 

Relevant articles and documents

Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold

This letter describes the discovery of a fused benzofuran scaffold viable for preparing a series of novel potent HCV NS5B polymerase non-nucleoside inhibitors. Designed on the basis of the functionalized benzofuran derivative nesbuvir (HCV-796), these com

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

HEPATITIS C INHIBITORS AND USES THEREOF

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

INHIBITORS OF HEPATITIS C VIRUS

A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN

Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of 5-cyclopropyl-2- (4-fluoro-phenyl-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran- 3-carboxylic acid methylamide or a pharmaceutically acceptable salt thereof with natural, recombinant or modified interferon, that effectively inhibit viral replication.